The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
No Access

Endogenous modulation of monoamine oxidase in schizophrenic and normal humans

Published Online:https://doi.org/10.1176/ajp.139.12.1567

Plasma from normal subjects and chronic schizophrenic patients produced nearly equal inhibitory effects on platelet and bovine brain monoamine oxidase (MAO) activity. Plasma from controls and patients with high platelet MAO activity caused less decrease in platelet MAO kinetic variables (Km, Vmax) than plasma from subjects with midrange or low MAO activity. When bovine striatal MAO was used, with serotonin as substrate, plasma from schizophrenic patients caused less decrease in Vmax than plasma from controls. These inhibitory effects are associated with the presence in plasma of one or more nonalbumin proteins with low molecular weight.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.